Unconventional isoquinoline-based SERMs elicit fulvestrant-like transcriptional programs in ER+ breast cancer cells

Unconventional isoquinoline-based SERMs elicit fulvestrant-like transcriptional programs in ER+ breast cancer cells

Abstract Estrogen receptor alpha (ERα) is a ligand-dependent master transcriptional regulator and key driver of breast cancer pathology. Small molecule hormones and competitive antagonists favor unique ERα conformational ensembles that elicit ligand-specific transcriptional programs in breast cancer...

Full description

Bibliographic Details
Main Authors:	G. R. Hancock, K. S. Young, D. J. Hosfield, C. Joiner, E. A. Sullivan, Y. Yildiz, M. Lainé, G. L. Greene, S. W. Fanning
Format:	Article
Language:	English
Published:	Nature Portfolio 2022-12-01
Series:	npj Breast Cancer
Online Access:	https://doi.org/10.1038/s41523-022-00497-9

Similar Items

The SERM/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells
by: Sean W Fanning, et al.
Published: (2018-11-01)

Fundación SERMES para la Investigación Clínica
by: Josefina Berlanga
Published: (2014-09-01)

Effect of estrogens on skin aging and the potential role of SERMs
by: Susan Stevenson, et al.
Published: (2007-10-01)

Insulin-like growth factor-binding protein-3 is induced by tamoxifen and fulvestrant and modulates fulvestrant response in breast cancer cells
by: Keenan L. Flynn, et al.
Published: (2024-11-01)

Economic Evaluation for Palbociclib Plus Fulvestrant vs Ribociclib Plus Fulvestrant and Abemaciclib Plus Fulvestrant in Endocrine-Resistant Advanced or Metastatic Breast Cancer in Italy
by: Colombo GL, et al.
Published: (2023-03-01)

Is There Room for SERMs or SARMs as Alternative Therapies for Adult Male Hypogonadism?
by: Vito A. Giagulli, et al.
Published: (2020-01-01)

Clinical and immune responses to neoadjuvant fulvestrant with or without enzalutamide in ER+/Her2− breast cancer
by: Anthony D. Elias, et al.
Published: (2024-10-01)

Phase II trial of fulvestrant plus enzalutamide in ER+/HER2− advanced breast cancer
by: Anthony D. Elias, et al.
Published: (2023-05-01)

Fulvestrant in the fight against ER-positive advanced breast cancer; lone soldier or an important partner?
by: Ashish Singh
Published: (2020-01-01)

Interleukin-6 Level in serm of Iraqi Patients on Maintenance Hemodialysis Therapy
by: Hind H. Abdul Wahid, et al.
Published: (2007-01-01)

Andrographolide Inhibits ER-Positive Breast Cancer Growth and Enhances Fulvestrant Efficacy via ROS-FOXM1-ER-α Axis
by: Tong Xu, et al.
Published: (2022-05-01)

Influência do estrogênio e dos moduladores seletivos dos receptores estrogênicos (SERMS) na vascularização tireoidea Estrogen and selective estrogen receptor modulators (SERMS) influence thyroid gland vascularization
by: Luiz Felipe Bittencourt de Araújo
Published: (2009-01-01)

Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models
by: Lorna Hopcroft, et al.
Published: (2023-08-01)

Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer
by: Lillian M. Smyth, et al.
Published: (2021-04-01)

ER+, HER2− advanced breast cancer treated with taselisib and fulvestrant: genomic landscape and associated clinical outcomes
by: Jessica W. Chen, et al.
Published: (2023-10-01)

Clinical and genetic risk factors for Fulvestrant treatment in post-menopause ER-positive advanced breast cancer patients
by: Jingyu Liu, et al.
Published: (2019-01-01)

Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant
by: Jill M. Spoerke, et al.
Published: (2016-05-01)

Isoquinoline alkaloids/
by: 343379 Shamma, Maurice
Published: (1972)

Synthesis of isoquinoline derivatives and a few simple reactions of isoquinoline /
by: 462890 Lim, Siew Boon, et al.
Published: (2007)

Fulvestrant in treatment for metastatic breast cancer
by: L. Yu. Vladimirova, et al.
Published: (2019-12-01)

Fulvestrant: One step at a time?
by: P Harish, et al.
Published: (2020-01-01)

Fulvestrant-induced toxic epidermal necrolysis
by: Macarena Morales-Conde, et al.
Published: (2019-05-01)

Effects of SERM (selective estrogen receptor modulator) treatment on growth and proliferation in the rat uterus
by: Eriksson Håkan, et al.
Published: (2003-05-01)

Selective estrogen receptor modulator (SERM) for the treatment of osteoporosis in postmenopausal women: focus on lasofoxifene
by: Luigi Gennari, et al.
Published: (2010-01-01)

Selective estrogen receptor modulators (SERMs) affect cholesterol homeostasis through the master regulators SREBP and LXR
by: Fernandez-Suarez, ME, et al.
Published: (2021)

Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models
by: Lorna Hopcroft, et al.
Published: (2023-08-01)

Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models
by: Lorna Hopcroft, et al.
Published: (2023-09-01)

Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer
by: Kamila Kaminska, et al.
Published: (2021-02-01)

Serm Immuno Fixation Electrophoresis as a Diagnostic Method for Monoclonal Gammopathies in Patients with Multiple Myeloma
by: Araz Muhammad Yousif, et al.
Published: (2019-05-01)

Factors Influencing Skin Aging and the Important Role of Estrogens and Selective Estrogen Receptor Modulators (SERMs)
by: Lephart ED, et al.
Published: (2022-08-01)

Agonistic activity of tamoxifen, a selective estrogen-receptor modulator (SERM), on arthritic ovariectomized mice
by: L.A.S. Silva, et al.
Published: (2017-11-01)

Insilico docking studies of daidzeion compounds as selective estrogen receptor modulator (SERMS) breast cancer
by: Suryani Yani, et al.
Published: (2018-01-01)

Revisiting Fulvestrant Dosing in Uncertain Economic Times
by: Amol Patel, et al.
Published: (2021-12-01)

Stereospecific lasofoxifene derivatives reveal the interplay between estrogen receptor alpha stability and antagonistic activity in ESR1 mutant breast cancer cells
by: David J Hosfield, et al.
Published: (2022-05-01)

In Vitro Effects of Oestrogens, Antioestrogens and SERMs on Pancreatic Solid Pseudopapillary Neoplasm-Derived Primary Cell Culture
by: Isabella Tognarini, et al.
Published: (2010-01-01)

The differential effects of bisphosphonates, SERMS (selective estrogen receptor modulators), and parathyroid hormone on bone remodeling in osteoporosis
by: Silvia Migliaccio, et al.
Published: (2007-04-01)

Hypolipidemic action of the SERM acolbifene is associated with decreased liver MTP and increased SR-BI and LDL receptors
by: Christian Lemieux, et al.
Published: (2005-06-01)

Triple combination targeting PI3K, ER, and CDK4/6 inhibits growth of ER‐positive breast cancer resistant to fulvestrant and CDK4/6 or PI3K inhibitor
by: Leena Karimi, et al.
Published: (2023-06-01)

Fulvestrant-Big Mac Index: Defining Inequality in Oncology
by: David O'Reilly, et al.
Published: (2021-12-01)

Palladium-catalysed synthesis of isoquinolines
by: Pilgrim, B, et al.
Published: (2011)